Myelofibrosis (MF), either appearing de novo (primary MF, PMF) or after a previous diagnosis of essential thrombocythemia or of polycythemia vera, is a progressive disease burdened by symptomatic splenomegaly, debilitating systemic symptoms, ineffective hematopoiesis, and overall reduced survival. Patients often present worsening cytopenias, including thrombocytopenia, secondary to progression of the disease as well as to cytoreductive treatment. Patients with MF and thrombocytopenia have few therapeutic options and there is limited information regarding the management of disease in these settings. This article reviews current evidence for the management of patients with MF and thrombocytopenia, in the era of JAK inhibitors.
Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy / Benevolo G.; Elli E.M.; Guglielmelli P.; Ricco A.; Maffioli M.. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - ELETTRONICO. - 61:(2020), pp. 1535-1547. [10.1080/10428194.2020.1728752]
Thrombocytopenia in patients with myelofibrosis: management options in the era of JAK inhibitor therapy
Guglielmelli P.Writing – Review & Editing
;
2020
Abstract
Myelofibrosis (MF), either appearing de novo (primary MF, PMF) or after a previous diagnosis of essential thrombocythemia or of polycythemia vera, is a progressive disease burdened by symptomatic splenomegaly, debilitating systemic symptoms, ineffective hematopoiesis, and overall reduced survival. Patients often present worsening cytopenias, including thrombocytopenia, secondary to progression of the disease as well as to cytoreductive treatment. Patients with MF and thrombocytopenia have few therapeutic options and there is limited information regarding the management of disease in these settings. This article reviews current evidence for the management of patients with MF and thrombocytopenia, in the era of JAK inhibitors.File | Dimensione | Formato | |
---|---|---|---|
10.1080@10428194.2020.1728752.pdf
Accesso chiuso
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
1.57 MB
Formato
Adobe PDF
|
1.57 MB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.